Security Snapshot

Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share (STRO) Institutional Ownership

CUSIP: 869367102

13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

7

Shares (Excl. Options)

290,038

Price

$24.91

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-1
Value change
+$29
Number of holders
7
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
16,607,375
SEC-reported price per share
$24.91
Insider filing price
$24.91
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 869367102.
  • 7 institutions reported positions in Q1 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 7 to 7 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $3,355,752 to $7,224,847.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 7 institutions filings for Q1 2026.

Open SEC evidence

Security key

869367102

Latest holder period

Q1 2026

13F holders

7

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
STRO
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 4.9% $2,937,877 4,115,250 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 2.5% -69% $1,493,679 -$2,892,242 2,092,281 -66% BlackRock, Inc. 30 Jun 2025
Affinity Asset Advisors, LLC 6.5% -16% $26,642,467 -$137,363,902 1,069,519 -84% Affinity Asset Advisors, LLC 31 Mar 2026
Samsara BioCapital, L.P. 6.4% $26,476,886 1,062,872 Srinivas Akkaraju 11 Feb 2026
Point72 Asset Management, L.P. 5.7% $23,590,623 946,829 Point72 Asset Management, L.P. 24 Apr 2026
PERCEPTIVE ADVISORS LLC 5.4% $22,370,431 898,025 Perceptive Advisors LLC 14 Apr 2026
MILLENNIUM MANAGEMENT LLC 1.3% -72% $5,240,663 -$112,268,464 210,378 -96% Millennium Management LLC 31 Mar 2026

As of 31 Mar 2026, 7 institutional investors reported holding 290,038 shares of Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share (STRO). This represents 1.7% of the company’s total 16,607,375 outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
31
Latest
Q1 2026
Rows shown
1-25 of 31
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 290,038 $7,224,847 +$29 $24.91 7
2025 Q4 290,039 $3,355,752 -$74,010,412 $11.57 7
2025 Q3 53,354,083 $46,329,126 -$1,641,183 $0.87 84
2025 Q2 55,585,121 $39,680,994 -$3,651,726 $0.71 100
2025 Q1 61,457,334 $39,985,859 -$10,841,219 $0.65 113
2024 Q4 63,895,959 $117,565,386 -$7,306,459 $1.84 122
2024 Q3 62,516,525 $216,373,636 -$1,660,759 $3.46 130
2024 Q2 63,167,394 $185,075,042 +$25,139,079 $2.93 119
2024 Q1 53,412,221 $301,719,025 +$2,094,339 $5.65 116
2023 Q4 55,648,249 $238,729,642 -$219,480 $4.29 113
2023 Q3 55,996,442 $194,308,615 +$5,622,550 $3.47 108
2023 Q2 54,105,078 $251,585,717 +$2,181,872 $4.65 119
2023 Q1 53,720,779 $247,499,715 +$10,470,599 $4.62 114
2022 Q4 49,984,035 $403,859,817 +$6,296,600 $8.08 116
2022 Q3 50,396,383 $279,697,401 +$23,514,794 $5.55 111
2022 Q2 46,245,672 $240,931,373 +$15,713,924 $5.21 111
2022 Q1 41,606,389 $341,990,813 -$38,514,469 $8.22 111
2021 Q4 39,677,298 $590,411,817 -$4,363,219 $14.88 114
2021 Q3 39,817,120 $752,214,523 -$26,368,206 $18.89 119
2021 Q2 41,241,047 $766,657,023 -$71,886,996 $18.59 121
2021 Q1 44,209,991 $1,005,487,689 +$114,863,310 $22.76 136
2020 Q4 39,392,744 $855,224,796 +$184,675,658 $21.71 132
2020 Q3 31,151,440 $313,088,624 +$67,545,691 $10.05 87
2020 Q2 23,997,579 $186,238,799 +$97,614,730 $7.76 76
2020 Q1 11,868,607 $116,270,683 +$7,872,102 $10.20 60
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .